In a prospective long-term follow-up of patients with locally advanced rectal cancer treated with radiochemotherapy and surgery, downstaging of tumor and nodal status were significant predictors for longer progression-free and overall survival. A high local control rate of trimodal treatment comes at the cost of considerable long-term toxicity, with patient-reported dissatisfaction of bowel function even years after treatment. Background: The risk/benefit ratio of any treatment can only be fully assessed if long-term results of both efficacy and toxicity are taken into account. Whereas the combined modality treatment of locally advanced rectal cancer (LARC) has considerably improved prognosis, particularly with regard to local control, long-term results-including patientreported outcomes-are underreported. Patients and Methods: Patients with LARC treated within a multicenter single-arm phase II study were prospectively assessed for at least 5 years after surgery. Study treatment consisted of capecitabine and oxaliplatin prior and concurrent to preoperative pelvic radiotherapy followed by total mesorectal excision. Progression-free survival time (first endpoint), overall survival time, and pattern of relapse were analyzed in the whole study population and in pre-planned exploratory subgroups. Patient-reported outcomes, including overall satisfaction with bowel, stoma, and urinary function, were assessed in 6-month intervals. Results: Five-year progression-free and overall survival rate was 61% (95% confidence interval [CI], 46%-73%) and 78% (95% CI, 63%-87%), respectively. Distant to local recurrence rate was 3:1, with only 8% of patients relapsing locally. Main predictors for recurrence in univariate analyses were tumor downstaging (hazard ratio, 0.16; 95% CI, 0.05-0.56; P ¼ .0011) and nodal downstaging (hazard ratio, 0.17; 95% CI, 0.06-0.52; P ¼ .0005). The self-reported burden of symptoms related to bowel function was high in up to one-third of patients. A total of 28% of patients were dissatisfied with their urinary, bowel, or stoma function for at least 1 observation period. Conclusion: Combined-modality treatment of LARC results in a high and durable local disease control rate, especially in patients with tumor and/or nodal downstaging, at the cost of relevant long-term toxicity. Long-term care is required for a proportion of patients with poor gastrointestinal and/or urinary function after multimodality therapy. Reporting of long-term follow-up, including patient-recorded outcomes should be mandatory for future trials in LARC.
Background
The prognosis for patients with rectal cancer has considerably improved during the past decade. 1 Today's standard multidisciplinary approach, allowing for accurate preoperative staging, optimized surgery with universal adoption of total mesorectal excision and improved radiotherapy techniques, was key to this step forward. 2, 3 The majority of patients with localized-including locally advanced-rectal cancer will become long-term survivors. 4 Even patients with stage 4 disease and few resectable distant metastases from rectal cancer have an approximately 20% probability to survive for more than 5 years after diagnosis. 5 This prospect needs to shift our focus away from short-term treatment results towards long-term outcomes, allowing a thorough assessment whether efficacy results outweigh long-term treatment sequelae. Whereas the treatment approach for patients with locally advanced rectal cancer (LARC) (ie, T3/T4 tumors with or without nodal involvement) is somewhat controversial, results of the pivotal German rectal cancer trial 6,7 made combined radiochemotherapy followed by surgery a standard approach. Despite efforts to improve treatment efficacy quoad vitam by incorporating new drugs into the radiochemotherapy regimen, [8] [9] [10] [11] [12] the backbone of combined preoperative treatment is still fluoropyrimidine single agent treatment, either intravenously or in its oral form (ie, capecitabine). 13 However, few of these recent trials 14, 15 report longterm outcomes. We prospectively assessed long-term efficacy and side effects in patients with LARC treated in a phase II trial 10 with capecitabine and oxaliplatin prior and concurrent to preoperative pelvic radiotherapy.
Patients and Methods
All patients were treated in a prospective, multicenter, single-arm phase II study with preoperative radiochemotherapy and surgery. 10 Patients with histologically confirmed locally advanced (ie, endosonographically or magnetic resonance imaging-assessed T3/4) tumors with or without nodal involvement, were included. Treatment consisted of 1 cycle of capecitabine plus oxaliplatin (XELOX) chemotherapy (capecitabine 1000 mg/m 2 twice a day on days 1 to 14 and oxaliplatin 130 mg/m 2 on day 1), followed by radiotherapy (1.8 Gy fractions 5 days per week for 5 weeks) plus 2 concomitant cycles of capecitabine plus oxaliplatin (CAPOX; capecitabine 825 mg/m 2 twice daily on days 1 to 14 and oxaliplatin 50 mg/m 2 on days 1 and 8; every 3 weeks). Surgery was recommended 5 weeks after the end of radiochemotherapy. The preferred approach of radical resection was total mesorectal excision with sphincter preservation. Administration of adjuvant chemotherapy was left to the treating oncologists' discretion. Details on patients, methods, treatment, and short-term results have been published. 10 Long-term follow-up was not part of the initial protocol. Therefore, patients were reconsented for this ethics-approved follow-up study. Patients who were lost to follow-up or died before reconsenting were also included in the survival analyses. The Expert Commission of the Professional Secret in Medical Research of the Swiss Federal Office for Public Health (FOPH) gave authorization for this.
Patients and treating physicians were contacted once yearly after completion of primary treatment, and the following data were collected: (1) Efficacy parameters: date and location (local/distant) of recurrence was recorded for the primary outcome of progressionfree survival (PFS; time between first day of neoadjuvant treatment until recurrence, progression, or death). Survival status was recorded for the secondary outcome of overall survival (OS); (2) Long-term side effects: bowel function was assessed in terms of number of bowel movements per day and regular use of constipating agents as well as fecal incontinence (yes/no). Urinary function was assessed in terms of presence or absence of incontinence. Overall patientreported satisfaction was assessed in terms of satisfaction with bowel, stoma, and urinary function on a 4-point scale (very good, Patients with tumor location upper/middle or middle/lower are subjects of both groups. They count twice in total number of patients. Clinical Colorectal Cancer September 2017 -241 good, poor, very poor); (3) Adherence to National Guidelines: modality and frequency of all performed follow-up examinations were recorded and compared with the Swiss Society of Gastroenterology guidelines (www.sggssg.ch). 16, 17 PFS and OS curves were calculated according to the KaplanMeier method for all patients. Exploratory subgroup analyses were preplanned for the following factors (groups, yes/no): tumor downstaging (T-stage), nodal downstaging (N-status), complete histopathologic response to neoadjuvant treatment (Dvorak regression grade 3 or 4), and grade 3 or 4 diarrhea or lymphopenia during neoadjuvant treatment and adjuvant chemotherapy. Nonstratified log-rank tests were performed to compare PFS and OS distributions among the subgroups. Hazard ratio (HR) and 95% confidence intervals (CIs) were presented. Subgroup analyses for patients with R0-resection versus all other patients was omitted because only 1 patient was classified R1; all other patients were classified R0. For descriptive reporting of patient-reported outcomes, the observation period was divided into 6-month periods, starting at the date of surgery.
Results

Study Population
A total of 51 patients out of 54 patients (94%) who completed the previously reported phase II study 10 were included into this prospective observational follow-up study. Three patients were lost to follow-up because 1 out of 6 centers decided not to participate in the follow-up study. 
Treatment
All patients underwent preoperative radiochemotherapy and surgery, as previously reported. 10 Results do not differ significantly from the previously reported entire study population with 11 patients (22%) achieving pathologic complete response, 22 patients (43%) tumor downstaging, and 24 patients (47%) nodal downstaging (Table 2 ). After surgery, 30 patients (59%) were treated with adjuvant chemotherapy; almost half of them (14 patients; 47%) with a fluoropyrimidine single agent regimen.
PFS and OS
At the time of analysis, 16 patients (32%) had been diagnosed with recurrence of disease, and 4 patients (8%) had died (ie, a total of 20 events for the primary endpoint PFS had occurred). Five-year PFS and OS rates were 61% (95% CI, 46%-73%) and 78% (95% CI, 63%-87%), respectively ( Figure 1 ). A total of 31 patients (61%) lived without recurrence of disease; the median PFS was not reached but is longer than 77.9 months or 6.5 years (twenty-fifth percentile for PFS is 21.5 months). Similarly, the median OS was not reached, with 39 patients (76%) being alive at the end of the observation period.
Local recurrences occurred in 4 patients (8%) only. The distant to local recurrence rate was 3:1. The median time to recurrence was 14.7 months (range, 7-65 months). The majority of patients relapsed without symptoms (10 out of 16 patients).
In pre-planned univariate subgroup analyses, the main predictors for prolonged PFS and OS were tumor downstaging and nodal downstaging (Table 3) . Whereas adjuvant chemotherapy (yes vs. no) was a significant adverse factor for recurrence, it was not for survival (Table 3) .
Long-Term Adverse Events
Bowel and Urinary Function. Seventeen (33%) of patients suffered fecal incontinence, and 16 (31%) patients were dependent 
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on regular use of constipating agents during at least 1 of the 6-monthly observation periods. Urinary incontinence was reported in 2 (4%) patients at one point during follow-up. The selfreported number of bowel movements per day was higher than 3 for the majority of patients during the first 3 years after initial surgery (Figure 2A ). Figure 2B shows satisfaction with urinary, bowel, or stoma function for each observation period. Whereas the number of patients for which data were available is variable and diminishing over time, it shows that some patients are dissatisfied for a very long time after treatment. As many as 14 (28%) of the 51 patients report "poor" or "very poor" satisfaction with urinary, bowel, or stoma function during at least one observation period.
Secondary Malignancies. Secondary malignant tumors were diagnosed in 6 patients. Three patients were curatively treated (carcinoma of the skin [2 patients] and thyroid [1 patient]). Three patients received palliative treatment for a carcinoma of the stomach (2 years after LARC), an esophageal carcinoma (3 years after LARC), and a carcinoma of the posterior wall of the bladder (5 years after LARC), respectively.
Adherence to Guidelines. For 90% of patients (N ¼ 46) a surveillance scheme was intended, 78% according to FAGAS (Fachgesellschaft der Schweizer Gastroenterologen) and 12% according to Swiss Society for Gastroenterology (SGG) Guidelines. 16, 17 Mean compliance to the surveillance scheme was 40.6% (SD, 18.2%) (ie, 40.6% of all guideline-suggested follow-up exams were actually completed).
Discussion
In this long-term follow-up report of a phase II study for patients with LARC treated with preoperative radiochemotherapy, tumor and nodal downstaging were the primary predictors of PFS (primary 
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Clinical Colorectal Cancer September 2017 -243 endpoint) and OS. The local recurrence rate was 8%, and the local to distant recurrence ratio was 1:3. The trade-off for this high local control rate is significant long-term toxicity, with 28% of patients reporting poor or very poor satisfaction with bowel, stoma, or urinary function, and 10% of patients experiencing severe diarrhea (> 9 bowel movements per day), sometimes years after primary treatment. Chronic diarrhea impacts on quality of life on many levels: it adversely affects functioning in relationships and job performance and leads to social isolation and depression. 18, 19 The main weakness of our study is the limited number of patients. Therefore our conclusions are merely hypothesis-generating. Also, during the follow-up time of our study, oxaliplatin was not established as a component of preoperative radiochemotherapy in LARC, because efficacy results remain conflicting despite at least 5 large phase III trials.
14,20-23 However, except for peripheral neuropathy, toxicity as compared with fluoropyrimidine alone was similar; therefore, our conclusions are generalizable to fluoropyrimidine-based radiochemotherapy in general. 24 Furthermore, the patient-reported outcomes were not collected with well-established standardized questionnaires (eg, European Organization for Research and Treatment of Cancer Quality of life questionnaires 25 ), but with simple yes/ no questions or estimations on 4-point scales (very poor, poor, good, very good). This approach was chosen in order to simplify the procedures; acknowledging that any result in our small and noncontrolled trial population would need to be confirmed in a larger setting. The strengths of our study are the prospectively planned follow-up time for more than 5 years in a homogeneous trial population, looking not only at efficacy parameters but also at long-term toxicity including patient-reported outcomes.
Local relapses in less than 10% of patients is in line with published long-term follow-up results of the German trial CAO/ARO/ AIO-94 (Surgical (CAO), radiooncological (ARO) and medical (AIO) oncology working groups of the German Cancer Society) and the European Organization for Research and Treatment of Cancer Quality (EORTC) 22921 trial, both landmark studies in the treatment of LARC. 6, 7, 26, 27 Detailed analyses of long-term treatment sequelae and particularly patient-reported outcomes were not part of these studies. With a median follow-up of 50 months, chronic grade 3 or worse diarrhea (in 7% and 9% of patients in the experimental and control arms, respectively) and fecal incontinence (in 6% of patients) were identified as the most frequent late toxicities in the German CAO/ARO/AIO-04 trial. 22 Documentation of toxicities within clinical trials over extended periods of time consumes a large amount of resources (staff, time, money). Similarly, planning a longterm follow-up of patient-reported outcomes is often not part of an initial clinical study protocol: not only more resources are needed but an increase in number of missing data over time and therefore a decrease in the robustness of any conclusion is feared. However, if the clinical problem is significant-and our data and that of others confirm this-methods need to be adapted to tackle it anyway. In summary, our report emphasizes that only long-term followup allows for weighing risks and benefits of curatively intended combined-modality treatment for LARC. Radiochemotherapy followed by surgery results in a high local control rate (8% local recurrences in our high-risk population). However, this stands at odds with a high rate of patient-reported dissatisfaction with local function. Long-term follow-up, preferably including patient-reported outcomes, should be mandatory in future trials for LARC, and predictors for long-term toxicity are urgently needed. Furthermore, the ongoing efforts to de-escalate local treatment for selected patients (PROSPECT trial: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery) 28 will be key to individualize the balance between treatment (long-term) toxicity and efficacy.
Clinical Practice Points
The local control rate for patients with LARC is high after multimodal treatment, especially for patients with tumor or nodal downstaging. The toxicity of multimodal treatment, and therefore the overall benefit/risk ratio, can only be fully assessed after long-term follow-up. A proportion of patients need long-term specialized care for gastrointestinal and/or urinary dysfunction after multimodal treatment. 
